Deals
Deal activity by volume related to metaverse increased by 150% year-on-year in 2022 in the pharmaceutical industry
Credit: Bert van Dijk/Getty images.
Powered by
Analysis of the key themes driving deal activity reveals that metaverse accounted for 21 pharmaceutical deals between 2018 and 2022, worth a total value of $97m, according to GlobalData’s Deals database covering mergers and acquisitions, private equity, venture financing, equity offerings and partnerships. The $50m venture financing by Unlearn AI was the largest disclosed deal in 2022, while the $1m equity offering by Vivacitas Oncology was the largest disclosed deal in 2021.
In volume terms, metaverse related deal activity increased by 150% year-on-year in 2022 and by 100% year-on-year in 2021.
Deal activity related to metaverse in the global pharmaceutical industry in the last five years
Top deals related to metaverse in the pharmaceutical industry in the last five years
Deal volume by deal type for metaverse related deals in the pharmaceutical industry in the last five years
Partnerships accounted for the highest number of deals in the last five years, with 10 deals, followed by equity offerings (5 deals), and venture financing (5 deals).
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals database provides comprehensive coverage across industries tracking market activity of global mergers & acquisitions, including asset acquisitions/divestments; private equity deals (PE); venture finance deals (VC); equity offerings, including IPOs, follow-on offerings, and private placements; debt offerings, including private placements, ESG bonds and loans; partnerships; and licensing agreements.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumored deals.
